[go: up one dir, main page]

NO20071058L - Risedronatsammensetninger og deres fremgangsmater for anvendelse - Google Patents

Risedronatsammensetninger og deres fremgangsmater for anvendelse

Info

Publication number
NO20071058L
NO20071058L NO20071058A NO20071058A NO20071058L NO 20071058 L NO20071058 L NO 20071058L NO 20071058 A NO20071058 A NO 20071058A NO 20071058 A NO20071058 A NO 20071058A NO 20071058 L NO20071058 L NO 20071058L
Authority
NO
Norway
Prior art keywords
risedronate
compositions
methods
polymorph
solvate
Prior art date
Application number
NO20071058A
Other languages
English (en)
Inventor
Pamela Jean Schofield
Jr David Ernest Burgio
Maurice Kent Gately
Jun Shi
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34958880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071058(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO20071058L publication Critical patent/NO20071058L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En fremgangsmåte omfattende å oralt administrere til et menneske eller annet pattedyr en farmasøytisk sammensetning omfattende fra omtrent 65 % til omtrent 110 % av den kumulativt effektive dosen av risedronat eller en farmasøytisk akseptabel syre, salt, ester, solvat eller polymorf derav ifølge en kontinuerlig doseringsplan på én, to eller tre etterfølgende dager per måned, er nyttig for å behandle eller forebygge osteoporose og andre metabolske lidelser.
NO20071058A 2004-07-23 2007-02-22 Risedronatsammensetninger og deres fremgangsmater for anvendelse NO20071058L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/897,897 US20050070504A1 (en) 2001-12-21 2004-07-23 Risedronate compositions and their methods of use
PCT/US2004/031975 WO2006022755A1 (en) 2004-07-23 2004-09-25 Risedronate compositions and their methods of use

Publications (1)

Publication Number Publication Date
NO20071058L true NO20071058L (no) 2007-02-22

Family

ID=34958880

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071058A NO20071058L (no) 2004-07-23 2007-02-22 Risedronatsammensetninger og deres fremgangsmater for anvendelse

Country Status (20)

Country Link
US (1) US20050070504A1 (no)
EP (1) EP1776123A1 (no)
JP (3) JP5377852B2 (no)
KR (2) KR20080083219A (no)
CN (1) CN101146542A (no)
AR (1) AR046036A1 (no)
AU (2) AU2004322703B2 (no)
BR (1) BRPI0418973A (no)
CA (1) CA2564898A1 (no)
IL (1) IL180907A0 (no)
IS (1) IS8597A (no)
MA (1) MA28778B1 (no)
MX (1) MX2007000967A (no)
NO (1) NO20071058L (no)
NZ (1) NZ552799A (no)
PE (1) PE20060144A1 (no)
RU (1) RU2007103306A (no)
TW (1) TWI351286B (no)
WO (1) WO2006022755A1 (no)
ZA (1) ZA200701308B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK2532004A3 (en) * 2001-12-21 2004-11-03 Procter & Gamble Method for the treatment of bone disorders
NZ535705A (en) * 2002-05-10 2007-08-31 Hoffmann La Roche Ibandronic acid for the treatment and prevention of osteoporosis
SG174628A1 (en) * 2002-12-20 2011-10-28 Hoffmann La Roche High dose ibandronate formulation
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
AU2011218625B2 (en) * 2004-05-24 2014-03-20 Theramex HQ UK Limited Dosage forms of risedronate
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
WO2007047327A2 (en) * 2005-10-12 2007-04-26 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
KR100844256B1 (ko) 2007-03-23 2008-07-07 코오롱제약주식회사 리세드로네이트와 비타민 ｄ를 포함하는 대사성 골질환치료용 약제조성물 및 이의 제조방법
WO2010014766A1 (en) * 2008-07-31 2010-02-04 Warner Chilcott Company, Llc Low dosage forms of risedronate or its salts
KR101379664B1 (ko) * 2008-09-23 2014-04-02 한림제약(주) 리세드론산 또는 그의 염 및 비타민 ｄ를 포함하는 약학 조성물
KR101102364B1 (ko) 2009-09-18 2012-01-03 한림제약(주) 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물
PT106978A (pt) * 2013-05-31 2014-12-02 Tecnimede Sociedade Tecnico Medicinal S A Composição sólida oral contendo ácido ibandrónico e vitamina d

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA777769A (en) * 1963-03-18 1968-02-06 H. Roy Clarence Substituted methylene diphosphonic acid compounds and detergent compositions
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
CA1339805C (en) * 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
CA1336328C (en) * 1988-04-11 1995-07-18 Walter G. Leonard Method of increasing bone density in humans
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5227506A (en) * 1989-09-06 1993-07-13 Merck & Co., Inc. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
NL8902727A (nl) * 1989-11-06 1991-06-03 Philips Nv Objecthouder voor ondersteuning van een object in een geladen deeltjesbundelsysteem.
DE69324684T2 (de) * 1992-06-30 1999-11-25 Procter & Gamble Pharmaceuticals, Inc. Arzneimitteln zur behandlung von arthritis die phosphonate und nsaids enthalten
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US6008206A (en) * 1994-09-21 1999-12-28 Merck & Co., Inc. Sodium alendronate preparation for local administration
US6750216B2 (en) * 1996-03-08 2004-06-15 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5730715A (en) * 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
CA2293815C (en) * 1997-06-11 2004-06-29 The Procter & Gamble Company Film-coated tablet for improved upper gastrointestinal tract safety
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6331533B1 (en) * 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
US6225801B1 (en) * 1999-01-14 2001-05-01 Lucent Technologies Inc. Article comprising electronic circuits and devices with magnetically programmable electrical resistance
JP2001253827A (ja) * 2000-02-15 2001-09-18 Pfizer Prod Inc 骨粗鬆症を治療するための組成物および方法
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
WO2001097788A2 (en) * 2000-06-20 2001-12-27 Novartis Ag Method of administering bisphosphonates
US6593310B1 (en) * 2000-11-21 2003-07-15 Arthropharm Pty. Ltd. Treatment of osteoporosis
US20030139378A1 (en) * 2001-12-13 2003-07-24 Daifotis Anastasia G. Liquid bisphosphonate formulations for bone disorders
NZ535705A (en) * 2002-05-10 2007-08-31 Hoffmann La Roche Ibandronic acid for the treatment and prevention of osteoporosis
US20040188316A1 (en) * 2003-03-26 2004-09-30 The Procter & Gamble Company Kit for pharmaceutical use

Also Published As

Publication number Publication date
CA2564898A1 (en) 2006-03-02
JP5377852B2 (ja) 2013-12-25
EP1776123A1 (en) 2007-04-25
JP5761274B2 (ja) 2015-08-12
MX2007000967A (es) 2007-07-11
JP2013231087A (ja) 2013-11-14
IL180907A0 (en) 2007-07-04
AU2004322703A1 (en) 2006-03-02
KR20070038115A (ko) 2007-04-09
PE20060144A1 (es) 2006-04-17
TW200603816A (en) 2006-02-01
MA28778B1 (fr) 2007-08-01
NZ552799A (en) 2010-04-30
KR20080083219A (ko) 2008-09-16
JP2015038135A (ja) 2015-02-26
AU2004322703B2 (en) 2010-12-02
TWI351286B (en) 2011-11-01
AR046036A1 (es) 2005-11-23
RU2007103306A (ru) 2008-09-10
IS8597A (is) 2007-01-24
CN101146542A (zh) 2008-03-19
ZA200701308B (en) 2008-07-30
WO2006022755A1 (en) 2006-03-02
US20050070504A1 (en) 2005-03-31
AU2011200905A1 (en) 2011-03-24
BRPI0418973A (pt) 2007-12-04
JP2008507513A (ja) 2008-03-13
JP5910698B2 (ja) 2016-04-27

Similar Documents

Publication Publication Date Title
NO20071058L (no) Risedronatsammensetninger og deres fremgangsmater for anvendelse
NO20076319L (no) Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
DK1487829T3 (da) Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte
NO20045403L (no) Nye tiofenamidiner, sammensetninger derav og fremgangsmater for behandling av komplementformidlede sykdommer og tilstander
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
BRPI0515500A (pt) derivados piridazina para inibição de estearoil-coa-desaturase
NO950774L (no) Fremgangsmåte for inhibering av bentap og nedsettelse av serumkolesterol
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
NO20062004L (no) Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
TW200728260A (en) Substituted-(quinazolinyl)phenyl thiophenyl-sulfonylureas, methods for making and intermediates thereof
BRPI0411673A (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
FR2903107B1 (fr) Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
HUP0202692A2 (hu) Interleukin-5 inhibitor hatású 6-azauracil-származékok, ezeket tartalmazó gyógyszerkészítmények és intermedierjeik
EP2155736A4 (en) NEW CARBAMOYLOXYARYL ALKANOYLARYLPIPERAZIN COMPOUND, PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUND, AND METHOD FOR TREATING PAIN, FEAR AND DEPRESSION BY PROVIDING THE COMPOUND
DK1784173T3 (da) Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater
MA27157A1 (fr) Methode de traitement d'affections osseuses.
DK1631574T3 (da) Colchicosidanaloge
NO20092413L (no) Pyrazolanaloger
MX2024003930A (es) Moduladores de trpml, sus composiciones y metodos de uso.
GEAP202516774A (en) Compactable oral formulations of ibutamoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application